[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"colonization\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:colonization":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,75],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100644853","genomic-and-phenotypic-diversity-of-carbapenemase-producing-escherichia-coli-strains-circulating-in-southern-france-100644853",false,"NCT07676513","Genomic and Phenotypic Diversity of Carbapenemase-producing Escherichia Coli Strains Circulating in Southern France.","Genomic and Phenotypic Diversity of Carbapenemase-producing Escherichia Coli Strains Circulating in Southern France. The \"CARBA-COLI\" Study","CARBACOLI","Inclusion Criteria:\n\n* Not applicable to this study of an existing collection of Carbapenemase-producing Enterobacteriaceae strains.\n\nExclusion Criteria:\n\n* Not applicable to this study of an existing collection of Carbapenemase-producing Enterobacteriaceae strains.","ALL",{"count":19,"type":20},163,"ESTIMATED","3 Years","OBSERVATIONAL","Carbapenemase-producing Enterobacteriaceae (CPE) are classified as emerging Highly Resistant Bacteria (eHRB) because they expose infected patients to the risk of treatment failure due to the strains' resistance to last-line β-lactams, carbapenems, and frequent co-resistance to other classes of antibiotics, leading to increased morbidity and mortality. Their high epidemiogenic potential has enabled their global spread. In France, the incidence of Carbapenemase-producing Enterobacteriaceae is rising sharply, both in colonization and in infections. Parallel to this increase, Escherichia coli has become the most common Carbapenemase-producing Enterobacteriaceae (35% of strains in 2024, National Research Committee data), surpassing Klebsiella pneumoniae (24%).\n\nThe investigators hypothesize that the increase in the prevalence of carbapenemase-producing Echerichia coli is associated with a diversification of clones, enzymes, and their variants, and may pose a threefold threat: i) the spread of genes encoding carbapenemases within pathogenic extraintestinal Echerichia coli (ExPEC) pathogroups responsible for urinary tract infections and bacteremias, with a high risk of resistance spreading in the community, ii) the silent spread of Echerichia coli strains producing OXA-48 variants with reduced carbapenem hydrolytic activity, OXA-244 and OXA-484, which are not detected or poorly detected by conventionally used screening media and iii) the emergence of New Dehli Metallo-beta-lactamase (NDM) variants with high hydrolytic activity, such as NDM-5, within Echerichia coli clones possessing Penicillin-Binding Proteins (PLPs) with low affinity for antibiotics, leading to very high-level resistance and a therapeutic dead end in infected patients.",[25,26,27,28],"Antibiotic Resistance","Enterobacteriaceae Infections","Carbapenem-Resistant Enterobacteriaceae Infection","Colonization",[30,27,28,26],"Escherichia coli","NOT_YET_RECRUITING","2026-06-24",{"date":34,"type":35},"2026-06-30","ACTUAL",{"date":37,"type":20},"2026-06-01",{"date":39,"type":20},"2028-06-01",{"name":41,"class":42},"Centre Hospitalier Universitaire de Nīmes","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":17,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":4},"100632176","phase-1-probiotic-delivered-to-the-small-intestine-changes-microbiota-100632176","NCT07510282","Probiotic Delivered to the Small Intestine Changes Microbiota","A Physiological Study on How Probiotic Delivered to the Small Intestine Changes Microbiota","Probiotic","Inclusion Criteria:\n\n* Capacity to obtain and sign informed consent before any study-related procedure\n* BMI range 18.5-31.9 kg\u002Fm2\n* Willing to abstain from regular consumption of probiotic supplements or food products containing probiotic bacteria (including fermented food and beverages).\n* Willing to abstain from regular consumption of supplements and medications known to alter gastrointestinal function or inflammatory status during the study.\n\nExclusion Criteria:\n\n* Smoking\n* Substance abuse\n* Pregnancy\n* Diagnosis of type 1 and\u002For type 2 diabetes\n* Current (or within the last 4 weeks prior to the study start) use of probiotic supplementation.\n* Immobile (defined as the inability to participate in all study-related procedures)\n* History of complicated gastrointestinal surgery\n* Diagnosed with inflammatory bowel disease (IBD)\n* Current diagnosis of psychiatric disease\u002Fs or syndromes\n* Current diagnosis of neurodegenerative disease\n* Systemic use of antibiotics and\u002For steroid medication in the last 4 months prior to inclusion\n* Use of any non-steroidal anti-inflammatory drug (NSAID) more than 3 times a week for the last 2 months\n* Consumption of any NSAID within 7 days of study start\n* Any condition which could substantially interfere with intestinal barrier function (e.g. gluten sensitivity, lactose intolerance, celiac disease, IBS, IBD) or in any other way with the outcome of the study, as decided by the principal investigator's discretion\n* Regular smoking, use of snuff, nicotine, cannabidiol narcotics\u002Fsupplements, or e-cigarette use\n* Drinking more than 9 standard cups of alcohol per week and\u002For more than 3 standard cups of alcohol per occasion\n* Regular use, for more than three times a week for the last 2 months and\u002For 7 days prior to inclusion, of medications which, according to the principal investigator, can have an anti-inflammatory effect or affect in any way the intestinal barrier function or have an impact on the study analysis (such as laxatives, anti-diarrheal, anti-cholinergic, etc.)\n* After being included in the study, starting any medication or treatment that could potentially influence the study participation and\u002For study analysis.",true,"25 Years","65 Years",{"count":56,"type":20},25,"INTERVENTIONAL",[59],"PHASE1","This study will determine whether encapsulation of probiotic bacteria using natural plant protein can enhance bacterial colonisation. Lactobacillus rhamnosus is an ideal strain for the intervention, as it has been shown to affect overall gut health, gut-brain axis, and brain function. Participants aged 25 to 65 years will be recruited and assessed on four occasions to compare the effects of the blood chemicals and bacterial composition in faeces of a 28-day ingestion of a yoghurt beverage with and without the probiotic strain of interest. The study window will be 70+\u002F13 days. This study will provide important information regarding the physiological function of probiotics in the small intestine. Understanding the underlying physiological effects of targeted probiotic delivery to the intestine and the impact on the microbiome is important for health outcomes.",[62,28],"Colonization, Asymptomatic",[50,64,28,65],"Microbiota","Dairy","2026-03-29",{"date":68,"type":35},"2026-04-03",{"date":70,"type":20},"2026-04-15",{"date":72,"type":20},"2026-12",{"name":74,"class":42},"University College Dublin",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":83,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":101},"100623433","predictive-score-in-patients-with-hematological-malignancies-colonized-by-multidrug-resistant-enterobacteriaceae-100623433","NCT07396571","Predictive Score in Patients With Hematological Malignancies Colonized by Multidrug-resistant Enterobacteriaceae","Development of a Predictive Infection Score in Patients With Hematological Malignancies Colonized by Multidrug-resistant Enterobacteriaceae","SCREEN-IN","Inclusion criteria\n\n* Patients admitted to Hematology departments with hematological diseases, including: myelodysplastic syndrome, acute myeloid leukemia, acute lymphoblastic leukemia, multiple myeloma, chronic lymphocytic leukemia, chronic myeloproliferative leukemias, lymphomas, or other hematological disorders.\n* Patients scheduled to receive treatment for their underlying hematological disease, including myeloablative\u002Fcytotoxic chemotherapy, conditioning chemotherapy for hematopoietic stem cell transplantation (autologous, allogeneic, or other types), lymphodepleting chemotherapy for CAR-T cell therapy, and\u002For other treatments expected to induce neutropenia.\n* Patients expected to develop neutropenia (neutrophil count \\\u003C 0.5 \\\\times 10\\^9\u002FL, or \\\u003C 1.0 \\\\times 10\\^9\u002FL when predicted to fall below 0.5 \\\\times 10\\^9\u002FL within the next 48 hours) in the coming days.\n* Those who have signed the informed consent form.\n* Participation in another study is permitted, provided it is observational and does not influence the potential colonization status.\n\nExclusion criteria\n\n* Psychiatric disorder or inability to understand or follow the protocol instructions.\n* Terminally ill patients or those with an estimated life expectancy of less than 30 days.\n* Previous enrollment in the study.\n* Known prior colonization by ESBL-producing Enterobacteriaceae (ESBL-E) or carbapenemase-producing Enterobacteriaceae (CPE).\n* Physician's discretion: The patient's attending physician prefers not to include the patient in the study.","18 Years",{"count":85,"type":20},535,"The goals of this observational study are to identify risk factors for ESBL-producing Enterobacterales and carbapenemase-producing Enterobacterales (CPE) colonization in oncohematological patients with severe neutropenia, and to develop and validate a predictive model of infection caused by ESBL-producing Enterobacterales and CPE in patients previously colonized by the same bacteria.\n\nThe main questions the study aims to answer are:\n\n* What are the risk factors for ESBL-producing Enterobacterales and CPE colonization in patients with severe neutropenia?\n* Can a predictive model be developed to accurately predict infections in the colonized patients?\n\nStudy Design \\& Participants: Participants will be screened after receiving neutropenia-inducing treatment (e.g., chemotherapy, chimeric antigen receptor T-cell (CAR-T) therapy, or others). A baseline rectal swab will be collected to assess initial colonization status, followed by weekly swabs throughout the duration of neutropenia. Patients will be followed for 90 days from initial screening, during which the study team will record any infections, with an additional 30-day follow-up period. All hospitalization data will be recorded.",[88,28,89,90,91],"Hemato-oncologic Patients","Neutropenia","Enterobacteria Non Susceptible to Carbapenem Carrier","ESBL-producing Enterobacteriaceae Infections","2026-02-27",{"date":94,"type":35},"2026-03-02",{"date":96,"type":20},"2026-02",{"date":98,"type":20},"2028-12",{"name":100,"class":42},"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla",15]